SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Burzynski Research Institute Inc – ‘10-Q’ for 5/31/20 – ‘EX-101.INS’

On:  Wednesday, 7/15/20, at 4:50pm ET   ·   For:  5/31/20   ·   Accession #:  1104659-20-83756   ·   File #:  0-23425

Previous ‘10-Q’:  ‘10-Q’ on 1/14/20 for 11/30/19   ·   Next:  ‘10-Q’ on 10/15/20 for 8/31/20   ·   Latest:  ‘10-Q’ on 1/16/24 for 11/30/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/15/20  Burzynski Research Institute Inc  10-Q        5/31/20   32:1.2M                                   Toppan Merrill/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    219K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     16K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     16K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     13K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     13K 
12: R1          Document and Entity Information                     HTML     39K 
13: R2          Balance Sheets                                      HTML     48K 
14: R3          Balance Sheets (Parenthetical)                      HTML     20K 
15: R4          Statements of Operations                            HTML     33K 
16: R5          Statement of Stockholders' Deficit                  HTML     27K 
17: R6          Statements of Cash Flows                            HTML     41K 
18: R7          Basis of Presentation                               HTML     18K 
19: R8          Economic Dependency                                 HTML     15K 
20: R9          Stock Options and Warrants                          HTML     24K 
21: R10         Loss Per Common Share                               HTML     14K 
22: R11         Income Taxes                                        HTML     41K 
23: R12         Stock Options and Warrants (Tables)                 HTML     21K 
24: R13         Income Taxes (Tables)                               HTML     37K 
25: R14         Basis of Presentation (Details)                     HTML     15K 
26: R15         Stock Options and Warrants (Details)                HTML     50K 
27: R16         Loss Per Common Share (Details)                     HTML     13K 
28: R17         Income Taxes (Details)                              HTML     39K 
29: R18         Income Taxes - Operating Loss Carryforwards         HTML     18K 
                (Details)                                                        
31: XML         IDEA XML File -- Filing Summary                      XML     46K 
30: EXCEL       IDEA Workbook of Financial Reports                  XLSX     25K 
 6: EX-101.INS  XBRL Instance -- bzyr-20200531                       XML    216K 
 8: EX-101.CAL  XBRL Calculations -- bzyr-20200531_cal               XML     50K 
11: EX-101.DEF  XBRL Definitions -- bzyr-20200531_def                XML     94K 
 9: EX-101.LAB  XBRL Labels -- bzyr-20200531_lab                     XML    352K 
10: EX-101.PRE  XBRL Presentations -- bzyr-20200531_pre              XML    208K 
 7: EX-101.SCH  XBRL Schema -- bzyr-20200531                         XSD     51K 
32: ZIP         XBRL Zipped Folder -- 0001104659-20-083756-xbrl      Zip     35K

‘EX-101.INS’   —   XBRL Instance — bzyr-20200531

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Created by Toppan Merrill -->
<!-- XBRL document created with Toppan Merrill Bridge 9.7.1.4 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 7/15/2020 8:46:13 AM -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:bzyr="http://www.burzynskiresearch.com/20200531" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:type="simple" xlink:href="bzyr-20200531.xsd"/>
<!-- Context Section -->
<context id="Duration_3_1_2020_To_5_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-05-31 </endDate>
</period>
</context>
<context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-05-31 </instant>
</period>
</context>
<context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-05-31 </instant>
</period>
</context>
<context id="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-02-29 </instant>
</period>
</context>
<context id="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-02-29 </instant>
</period>
</context>
<context id="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-05-31 </instant>
</period>
</context>
<context id="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-02-28 </instant>
</period>
</context>
<context id="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-02-28 </instant>
</period>
</context>
<context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-05-31 </instant>
</period>
</context>
<context id="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-02-29 </instant>
</period>
</context>
<context id="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-02-28 </instant>
</period>
</context>
<context id="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 1998-06-01 </startDate>
<endDate> 1998-06-01 </endDate>
</period>
</context>
<context id="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 1997-06-01 </startDate>
<endDate> 1997-06-01 </endDate>
</period>
</context>
<context id="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 1996-09-14 </startDate>
<endDate> 1996-09-14 </endDate>
</period>
</context>
<context id="Duration_3_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2019_To_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-03-01 </startDate>
<endDate> 2019-05-31 </endDate>
</period>
</context>
<context id="As_Of_2_28_2021">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2021-02-28 </instant>
</period>
</context>
<context id="As_Of_5_31_2019">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2019-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2019">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2019-02-28 </instant>
</period>
</context>
<context id="As_Of_2_29_2020">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2020-02-29 </instant>
</period>
</context>
<context id="As_Of_6_30_2020">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2020-06-30 </instant>
</period>
</context>
<context id="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2012-07-05 </instant>
</period>
</context>
<context id="As_Of_5_31_2020_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis"> us-gaap:LatestTaxYearMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-05-31 </instant>
</period>
</context>
<context id="As_Of_5_31_2020">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2020-05-31 </instant>
</period>
</context>
<context id="Duration_3_1_2020_To_5_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:InternalRevenueServiceIRSMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2020_To_5_31_2020_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-05-31 </endDate>
</period>
</context>
<context id="As_Of_5_31_2020_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-05-31 </instant>
</period>
</context>
<context id="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2012-07-05 </startDate>
<endDate> 2012-07-05 </endDate>
</period>
</context>
<context id="Duration_3_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2020_To_5_31_2020">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2019_To_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-03-01 </startDate>
<endDate> 2019-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2019_To_5_31_2019">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<startDate> 2019-03-01 </startDate>
<endDate> 2019-05-31 </endDate>
</period>
</context>
<!-- Unit Section -->
<unit id="Unit16">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> xbrli:shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Unit15">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> bzyr:item </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Unit14">
<measure> xbrli:pure </measure>
</unit>
<unit id="Unit13">
<measure> bzyr:item </measure>
</unit>
<unit id="Unit12">
<measure> xbrli:shares </measure>
</unit>
<unit id="Unit1">
<measure> iso4217:USD </measure>
</unit>
<!-- Tuple Section --> <!-- Element Section -->
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 138217 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2019_To_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 138217 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 83317 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 83317 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:ClassOfWarrantOrRightsExercisePeriod contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember"> P10Y </bzyr:ClassOfWarrantOrRightsExercisePeriod>
<bzyr:ClassOfWarrantOrRightsWarrantsExercisedNumber contextRef="As_Of_5_31_2020_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit12" decimals="INF"> 0 </bzyr:ClassOfWarrantOrRightsWarrantsExercisedNumber>
<bzyr:ClassOfWarrantOrRightsWarrantsVesting contextRef="Duration_3_1_2020_To_5_31_2020_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit12" decimals="INF"> 0 </bzyr:ClassOfWarrantOrRightsWarrantsVesting>
<bzyr:ClinicalTrialExpensesPaid contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 316719 </bzyr:ClinicalTrialExpensesPaid>
<bzyr:ClinicalTrialExpensesPaid contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 281978 </bzyr:ClinicalTrialExpensesPaid>
<bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination contextRef="Duration_3_1_2020_To_5_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember"> P3Y </bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination>
<bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 171623 </bzyr:NetOperatingLossCarryForwardIndefinitely>
<bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit13" decimals="INF"> 0 </bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval>
<bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard contextRef="As_Of_5_31_2020" unitRef="Unit14" decimals="3"> 0.810 </bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard>
<bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit14" decimals="2"> 0.10 </bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement>
<bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit14" decimals="2"> 0.80 </bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards>
<bzyr:RemainingSharesToVestUponFirstClosingOfAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit12" decimals="INF"> 1000000 </bzyr:RemainingSharesToVestUponFirstClosingOfAgreement>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit13" decimals="INF"> 1 </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans>
<bzyr:SharesVestingUponExecutionOfAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit12" decimals="INF"> 1000000 </bzyr:SharesVestingUponExecutionOfAgreement>
<bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards contextRef="As_Of_5_31_2020_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember" unitRef="Unit1" decimals="0"> 627695 </bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards>
<bzyr:WarrantOrRightFairValuePerWarrant contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit15" decimals="2"> 0.16 </bzyr:WarrantOrRightFairValuePerWarrant>
<dei:AmendmentFlag contextRef="Duration_3_1_2020_To_5_31_2020"> false </dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Duration_3_1_2020_To_5_31_2020"> --02-29 </dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Duration_3_1_2020_To_5_31_2020"> Q1 </dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Duration_3_1_2020_To_5_31_2020"> 2021 </dei:DocumentFiscalYearFocus>
<dei:DocumentPeriodEndDate contextRef="Duration_3_1_2020_To_5_31_2020"> 2020-05-31 </dei:DocumentPeriodEndDate>
<dei:DocumentType contextRef="Duration_3_1_2020_To_5_31_2020"> 10-Q </dei:DocumentType>
<dei:EntityCentralIndexKey contextRef="Duration_3_1_2020_To_5_31_2020"> 0000724445 </dei:EntityCentralIndexKey>
<dei:EntityCommonStockSharesOutstanding contextRef="As_Of_6_30_2020" unitRef="Unit12" decimals="INF"> 131448444 </dei:EntityCommonStockSharesOutstanding>
<dei:EntityCurrentReportingStatus contextRef="Duration_3_1_2020_To_5_31_2020"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityEmergingGrowthCompany contextRef="Duration_3_1_2020_To_5_31_2020"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityFilerCategory contextRef="Duration_3_1_2020_To_5_31_2020"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntityInteractiveDataCurrent contextRef="Duration_3_1_2020_To_5_31_2020"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityRegistrantName contextRef="Duration_3_1_2020_To_5_31_2020"> BURZYNSKI RESEARCH INSTITUTE INC </dei:EntityRegistrantName>
<dei:EntityShellCompany contextRef="Duration_3_1_2020_To_5_31_2020"> false </dei:EntityShellCompany>
<dei:EntitySmallBusiness contextRef="Duration_3_1_2020_To_5_31_2020"> true </dei:EntitySmallBusiness>
<us-gaap:AccountsPayableCurrent contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 60805 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 141866 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 111635 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 112698 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 123373793 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 123739088 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 316719 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2019_To_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 316719 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 281978 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 281978 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit12" decimals="INF"> 1600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit12" decimals="INF"> 1600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:Assets contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 19853 </us-gaap:Assets>
<us-gaap:Assets contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 9302 </us-gaap:Assets>
<us-gaap:AssetsCurrent contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 19853 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 9302 </us-gaap:AssetsCurrent>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 163 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_2_28_2019" unitRef="Unit1" decimals="0"> 708 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_5_31_2019" unitRef="Unit1" decimals="0"> 3110 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 163 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 2402 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -163 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit16" decimals="2"> 0.10 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit12" decimals="INF"> 2000000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_2_29_2020" unitRef="Unit1"/>
<us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_5_31_2020" unitRef="Unit1"/>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_2_29_2020" unitRef="Unit16" decimals="INF"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_5_31_2020" unitRef="Unit16" decimals="INF"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_2_29_2020" unitRef="Unit12" decimals="INF"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_5_31_2020" unitRef="Unit12" decimals="INF"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="As_Of_2_29_2020" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="As_Of_5_31_2020" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="As_Of_2_29_2020" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="As_Of_2_28_2021" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockValue contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 131449 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 131449 </us-gaap:CommonStockValue>
<us-gaap:DeferredTaxAssetsNet contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 0 </us-gaap:DeferredTaxAssetsNet>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 210460 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">NOTE C.<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 33pt 0pt 0pt;"></font>STOCK OPTIONS AND WARRANTS</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">At May 31, 2020, the Company had one stock-based employee compensation plan, which is described below.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company.  The options vested as follows:</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;"> </font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> </font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">    </font></p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Vesting Date</font></p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 400,000</font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">options</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">September 14, 1996</font></p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 100,000</font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">options</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">June 1, 1997</font></p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 100,000</font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">options</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">June 1, 1998</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The options are valid in perpetuity.  None of the options have been exercised as of May 31, 2020.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company accounts for share-based payments to non-employees in accordance with the guidance provided by FASB ASC 718, Compensation – Stock Compensation to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to 10% of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of 2,000,000 shares of the Company’s Common Stock, exercisable at $0.10 per share with a ten year exercise period, with 1,000,000 shares vesting upon execution of the agreement (the "Initial Warrants") and the remaining 1,000,000 shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The fair market value of the vested warrants as of the date of grant was measured using the Black-Scholes option pricing model and totaled approximately $160,000 or $0.16 per warrant. As of May 31, 2020, none of the aforementioned warrants have been exercised and no additional vesting has occurred. The Marketing Agreement was terminated effective as of July 5, 2019 pursuant to its terms. The Initial Warrants are currently outstanding and can still be exercised.</font> </p><div /></div> </div>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit16" decimals="2"> 0.00 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit16" decimals="2"> 0.00 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">NOTE D.<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 33pt 0pt 0pt;"></font>LOSS PER COMMON SHARE</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company accounts for loss per share in accordance with FASB ASC 260, </font><font style="display:inline;font-style:italic;font-size:10pt;">Earnings per Share</font><font style="display:inline;font-size:10pt;">. Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three months ended May 31, 2020 and 2019, 1,600,000 warrants and stock options were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.</font> </p><div /></div> </div>
</us-gaap:EarningsPerShareTextBlock>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit14" decimals="2"> 0.21 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit14" decimals="2"> 0.21 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 135577 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 118285 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -468314 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -457970 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">NOTE E.<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 33pt 0pt 0pt;"></font>INCOME TAXES</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company follows the provisions of FASB ASC 740, </font><font style="display:inline;font-style:italic;font-size:10pt;">Income Taxes</font><font style="display:inline;font-size:10pt;">.  The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The federal income tax returns of the Company for 2019, 2018, and  2017 are subject to examination by the IRS, generally for three years after they are filed.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The actual provision for income tax for the three months ended May 31, 2020 and 2019 differ from the amounts computed by applying the U.S. federal income tax rate of 21% to the pretax loss as a result of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td colspan="5" valign="bottom" style="width:31.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Three Months Ended May 31, </font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">    </font></p> </td> <td colspan="2" valign="bottom" style="width:14.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">    </font></p> </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Expected income tax benefit </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (96,174)</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (98,346)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Effect of expenses deducted directly by Dr. Burzynski </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 96,174</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 98,346</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Nondeductible expenses and other adjustments </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 19,462</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 2,809</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Change in valuation allowance </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (19,462)</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (2,809)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">State tax </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Income tax expense </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">At May 31, 2020, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $210,460. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income.  The Company has no historical earnings on which to base an expectation of future taxable income.  Accordingly, a full valuation allowance for deferred tax assets has been provided.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017 would carryforward indefinitely, and would apply to 80% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also suspended the NOL limit of 80% of taxable income, but the NOLs generated in 2018 and forward will still carryforward indefinitely.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">As of May 31, 2020, the Company has net operating loss carryforwards in the amount of $627,695 that will expire between 2023 and 2038, and $171,623 that will carryforward indefinitely.</font> </p><div /></div> </div>
</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -2809 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -19462 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 98346 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 96174 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -98346 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -96174 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 2809 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 19462 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -3867 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 81061 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 7932 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 1063 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -11715 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -10388 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:Liabilities contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 172440 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 254564 </us-gaap:Liabilities>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 19853 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 9302 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 138217 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 83317 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -135815 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -83480 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -468314 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -468314 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -468314 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2019_To_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="0"> -468314 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -457970 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -457970 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -457970 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="0"> -457970 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:OperatingExpenses contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 468314 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 457970 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> -468314 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> -457970 </us-gaap:OperatingIncomeLoss>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">NOTE A.<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 33pt 0pt 0pt;"></font>BASIS OF PRESENTATION</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The financial statements of Burzynski Research Institute, Inc. (the “Company”), a Delaware corporation, include expenses incurred related to clinical trials, which were sanctioned by the U.S. Food and Drug Administration (FDA) in 1993, for Antineoplaston drugs used in the treatment of cancer.  These expenses are incurred directly by S.R. Burzynski, M.D., Ph.D. (Dr. Burzynski or “SRB”) on behalf of the Company and have been reported as research and development costs and as additional paid-in capital.  Other funds received from Dr. Burzynski have also been reported as additional paid-in capital.  Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements.  Dr. Burzynski is the President, Chairman of the Board and owner of approximately 81.0% of the outstanding common stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons.” </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company and Dr. Burzynski have entered into various agreements. The License Agreement between the Company and Dr. Burzynski provided the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once the drug is approved for sale by the FDA. On July 2, 2019, such License Agreement terminated upon the expiration of the last patent licensed to the Company under such agreement. As such, the Company does not currently own any patents or have licenses to any patents with respect to Antineoplastons.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. The Company’s investigational new drug application (“IND”) 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of May 31, 2020 and February 29, 2020, results of operations for the three months ended May 31, 2020 and 2019, and cash flows for the three months ended May 31, 2020 and 2019.  All adjustments are of a normal recurring nature.  The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.  These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 29, 2020.</font> </p><div /></div> </div>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:PrepaidExpenseCurrent contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> 19690 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> 9302 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:ProceedsFromContributedCapital contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 138217 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:ProceedsFromContributedCapital contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 83317 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit1" decimals="0"> 332737 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 339685 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> -123657829 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> -124115799 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:Revenues contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit1" decimals="0"> 0 </us-gaap:Revenues>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td colspan="5" valign="bottom" style="width:31.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Three Months Ended May 31, </font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">    </font></p> </td> <td colspan="2" valign="bottom" style="width:14.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">    </font></p> </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Expected income tax benefit </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (96,174)</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (98,346)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Effect of expenses deducted directly by Dr. Burzynski </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 96,174</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 98,346</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Nondeductible expenses and other adjustments </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 19,462</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 2,809</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Change in valuation allowance </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (19,462)</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> (2,809)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">State tax </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">Income tax expense </font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">  —</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p><div /></div> </div>
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF"> 600000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;"> </font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">  </p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;"> </font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">    </font></p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Vesting Date</font></p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 400,000</font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">options</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">September 14, 1996</font></p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 100,000</font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">options</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">June 1, 1997</font></p> </td> </tr> <tr> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;"> 100,000</font></p> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">options</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">  </p> </td> <td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;font-size:10pt;">June 1, 1998</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p><div /></div> </div>
</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF"> 400000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF"> 100000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF"> 100000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit16" decimals="2"> 0.35 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharesOutstanding contextRef="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="INF"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2019" unitRef="Unit1" decimals="0"> -186648 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 121705250 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="0"> -122023347 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2019" unitRef="Unit1" decimals="0"> -200026 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 122160186 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="0"> -122491661 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> -152587 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_29_2020" unitRef="Unit1" decimals="0"> -152587 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 123373793 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_29_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="0"> -123657829 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> -245262 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2020" unitRef="Unit1" decimals="0"> -245262 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="0"> 123739088 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="0"> -124115799 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_3_1_2020_To_5_31_2020">
<div> <div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">NOTE B.<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 33pt 0pt 0pt;"></font>ECONOMIC DEPENDENCY</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit.  Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> </font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice.  In the past, a portion of Dr. Burzynski’s patients have been admitted and treated as part of the clinical trial programs.  The Company’s IND 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA.  The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA.  These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</font> </p><div /></div> </div>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_3_1_2020_To_5_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember" unitRef="Unit1" decimals="0"> 160000 </us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_3_1_2019_To_5_31_2019" unitRef="Unit12" decimals="0"> 131448444 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_3_1_2020_To_5_31_2020" unitRef="Unit12" decimals="0"> 131448444 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<!-- Footnote Section -->
</xbrl>

↑Top
Filing Submission 0001104659-20-083756   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., Apr. 19, 5:21:57.1am ET